AMSBIO launches new range of biosimilar antibodies for research use

AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.

AMSBIO launches new range of biosimilar antibodies for research use
Image Credit: AMSBIO

Investigating the biological effects of a drug or doing proof of concept assay development, requires a source of the drug. Typically, it is difficult to obtain original pharmaceutical grade biotherapeutic drugs for research use, rather than a clinical application. Consequently, biological compounds almost identical to a reference biologic drug (biosimilars) that have been approved by governmental regulatory authorities for medical treatment are vital research tools.

To develop an effective biologic drug, it is important to synthesize a reference antibody. A reference antibody can greatly facilitate the downstream development of a new biologic drug and can help identify critical cell lines, reagents and performance characteristics. AMSBIO's new range of biosimilar antibodies for research use avoid the need to source an expensive therapeutic product and enable fast and inexpensive assay development.

One of the main challenges in analyzing the impact of biosimilars is obtaining a validated positive control for in-situ analysis. For this task - FFPE cytosections of HEK293T cell pellet that over-express targeted proteins are available from AMSBIO. These cells are obtained by transfection of a sequenced verified cDNA clones transfected into HEK293T cells and the expression is verified by western blot and IHC analysis.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2023, March 23). AMSBIO launches new range of biosimilar antibodies for research use. AZoLifeSciences. Retrieved on March 04, 2024 from https://www.azolifesciences.com/news/20210715/AMSBIO-launches-new-range-of-biosimilar-antibodies-for-research-use.aspx.

  • MLA

    AMS Biotechnology. "AMSBIO launches new range of biosimilar antibodies for research use". AZoLifeSciences. 04 March 2024. <https://www.azolifesciences.com/news/20210715/AMSBIO-launches-new-range-of-biosimilar-antibodies-for-research-use.aspx>.

  • Chicago

    AMS Biotechnology. "AMSBIO launches new range of biosimilar antibodies for research use". AZoLifeSciences. https://www.azolifesciences.com/news/20210715/AMSBIO-launches-new-range-of-biosimilar-antibodies-for-research-use.aspx. (accessed March 04, 2024).

  • Harvard

    AMS Biotechnology. 2023. AMSBIO launches new range of biosimilar antibodies for research use. AZoLifeSciences, viewed 04 March 2024, https://www.azolifesciences.com/news/20210715/AMSBIO-launches-new-range-of-biosimilar-antibodies-for-research-use.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AMSBIO Expands EU Operations